176 related articles for article (PubMed ID: 28651104)
1. Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.
Chen L; Guo P; Zhang Y; Li X; Jia P; Tong J; Li J
Leuk Res; 2017 Sep; 60():44-52. PubMed ID: 28651104
[TBL] [Abstract][Full Text] [Related]
2. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
Kim Y; Eom JI; Jeung HK; Jang JE; Kim JS; Cheong JW; Kim YS; Min YH
Biomed Pharmacother; 2015 Jul; 73():87-96. PubMed ID: 26211587
[TBL] [Abstract][Full Text] [Related]
3. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
4. [The Effects and Regulatory Mechanism of Targeting CXC Chemokine Receptor 1/2 Combined with Ara-C on the Malignant Biological Behaviors of U937 Cells of Acute Myeloid Leukemia].
Liu YQ; Shen JZ; Yin Y; Chen YT; Yang H; Tang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):364-376. PubMed ID: 37096507
[TBL] [Abstract][Full Text] [Related]
5. Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
Chiou JT; Hsu CC; Hong YC; Lee YC; Chang LS
Biochem Pharmacol; 2023 May; 211():115494. PubMed ID: 36924905
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
[TBL] [Abstract][Full Text] [Related]
7. Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance.
Cheong JW; Kim Y; Eom JI; Jeung HK; Min YH
Mol Med Rep; 2016 Apr; 13(4):3433-40. PubMed ID: 26935591
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y
Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A; Linke A; Cebula B; Robak T; Smolewski P
Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
12. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
14. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
15. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.
Fernandes Â; Azevedo MM; Pereira O; Sampaio-Marques B; Paiva A; Correia-Neves M; Castro I; Ludovico P
Oncotarget; 2015 Oct; 6(31):31428-40. PubMed ID: 25537507
[TBL] [Abstract][Full Text] [Related]
17. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Walsby E; Lazenby M; Pepper C; Burnett AK
Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
[TBL] [Abstract][Full Text] [Related]
18. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
20. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]